Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-based chemotherapy.
Calbindin-D, a vitamin D-dependent calcium-binding protein of 28 kD, is found predominantly in the distal tubules of the kidney and central nervous system tissues in humans. To evaluate damage to the renal tubules caused by cisplatin-based chemotherapy, levels of urinary and serum calbindin-D were determined in patients treated with cisplatin- or carboplatin-based chemotherapies using a highly sensitive enzyme immunoassay system developed in our laboratory. Levels of urinary 28-kD calbindin-D were also determined in patients with benign and malignant urological diseases. The mean urinary calbindin-D level was 2.44 + or - 0.31 (mean + or - SE) ng/mg creatinine in 40 healthy subjects. Urinary calbindin-D levels were elevated (>10 ng/mg creatinine) in 2 of 33 patients (6%) with benign and 1 of 50 (2%) with malignant urological diseases. Urinary calbindin-D levels were significantly increased after cisplatin-based chemotherapy in 14 patients, with peaks (71.8 + or - 13.5 ng/mg creatinine) being found 8 days after administration of cisplatin, and then a gradual return to the baseline. On the other hand, 7 patients receiving carboplatin-based chemotherapy demonstrated no significant elevation (highest level 7.7 + or - 2.5 ng/mg creatinine). In 7 patients treated with cisplatin-based chemotherapy the serum calbindin-D level was also raised after treatment, with a good correlation to urinary values. These findings suggest that urinary and serum calbindin-D may be kidney-derived and that 28-kDa calbindin-D is a useful marker for damage to the distal renal tubules associated with cisplatin-based chemotherapy.
Takashi
M
M
Department of Urology, Nagoya University School of Medicine, Nagoya, Japan.
Zhu
Y
Y
Miyake
K
K
Kato
K
K
D000118:Acetylglucosaminidase / Q000652:urine; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood / Q000652:urine*; D064026:Calbindins; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D003404:Creatinine / Q000652:urine; D005260:Female; D052776:Female Urogenital Diseases / Q000652:urine; D006801:Humans; D007124:Immunoenzyme Techniques; D007686:Kidney Tubules, Distal / Q000187:drug effects*; D008297:Male; D052801:Male Urogenital Diseases; D008875:Middle Aged; D064030:S100 Calcium Binding Protein G / Q000097:blood / Q000652:urine*; D014571:Urologic Neoplasms / Q000188:drug therapy / Q000652:urine; D001613:beta 2-Microglobulin / Q000652:urine
D000970:Antineoplastic Agents; D015415:Biomarkers; D064026:Calbindins; D064030:S100 Calcium Binding Protein G; D001613:beta 2-Microglobulin; D003404:Creatinine; D016190:Carboplatin; D000118:Acetylglucosaminidase; D002945:Cisplatin